These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19744845)

  • 1. On the superiority of BDP/FF HFA pMDI fixed combination over the free combination of BDP CFC pMDI and FF DPI.
    García Arieta A
    Respir Med; 2009 Dec; 103(12):1969-70; author reply 1971-2. PubMed ID: 19744845
    [No Abstract]   [Full Text] [Related]  

  • 2. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
    Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.
    Dhillon S; Keating GM
    Drugs; 2006; 66(11):1475-83; discussion 1484-5. PubMed ID: 16906779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.
    Huchon G; Magnussen H; Chuchalin A; Dymek L; Gonod FB; Bousquet J
    Respir Med; 2009 Jan; 103(1):41-9. PubMed ID: 18977646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect of beclometasone/formoterol in asthma patients after methacholine-induced bronchoconstriction: A noninferiority study using metered dose vs. dry powder inhaler.
    Singh D; van den Berg F; Leaker B; Corradi M; Jabbal S; Collarini S; Mongelli V; Santoro L; Piccinno A; Biondaro S; Lipworth B
    Br J Clin Pharmacol; 2019 Apr; 85(4):729-736. PubMed ID: 30586199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
    Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchoprotective and bronchodilator effects of an HFA pMDI vs. a CFC pMDI and a DPI containing formoterol in asthma patients.
    Langley SJ; Houghton CM; Singh SD
    Respiration; 2005; 72 Suppl 1():35-7. PubMed ID: 15915011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():28-34. PubMed ID: 15915010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bronchodilation of formoterol administered with budesonide: device and formulation effects.
    Miller CJ; Senn S; Mezzanotte WS
    Contemp Clin Trials; 2008 Mar; 29(2):114-24. PubMed ID: 17625985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of BDP/formoterol fixed vs two single inhalers in asthma treatment.
    Brüggenjürgen B; Ezzat N; Kardos P; Buhl R
    Allergy; 2010 Sep; 65(9):1108-15. PubMed ID: 20121768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids.
    Hampel FC; Martin P; Mezzanotte WS
    J Asthma; 2008 May; 45(4):265-72. PubMed ID: 18446589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.
    Papi A; Paggiaro PL; Nicolini G; Vignola AM; Fabbri LM;
    Eur Respir J; 2007 Apr; 29(4):682-9. PubMed ID: 17107988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol pMDIs in asthmatic children.
    Chawes BL; Piccinno A; Kreiner-Møller E; Vissing NH; Poorisrisak P; Mortensen L; Nilson E; Bisgaard A; Dossing A; Deleuran M; Skytt NL; Samandari N; Sergio F; Ciurlia G; Poli G; Acerbi D; Bisgaard H
    Br J Clin Pharmacol; 2013 Apr; 75(4):1081-8. PubMed ID: 22978252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
    Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
    Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status.
    Brusselle G; Peché R; Van den Brande P; Verhulst A; Hollanders W; Bruhwyler J
    Respir Med; 2012 Jun; 106(6):811-9. PubMed ID: 22357130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI.
    Singh D; Collarini S; Poli G; Acerbi D; Amadasi A; Rusca A
    Br J Clin Pharmacol; 2011 Dec; 72(6):932-9. PubMed ID: 21615456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.